Last reviewed · How we verify
Optive, Ophthalmic Solution
At a glance
| Generic name | Optive, Ophthalmic Solution |
|---|---|
| Also known as | Optive, artificial tears, Optive Fusion UD |
| Sponsor | Michael D. Straiko, MD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease (PHASE3)
- Predicting the Success of Dry Eye Disease Interventions Using Clinical Tests (PHASE4)
- An Observational Study to Assess Optive MEGA-3 (OM3) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)
- An Observational Study to Assess Next Generation Emulsion Preservative Free Eye Drops (NGE-UD) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)
- Performance of Systane PRO Versus Refresh Optive Mega-3 (PHASE4)
- The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction (NA)
- Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive® (PHASE1)
- Artificial Tears, Tear Lipids and Tear Film Dynamics (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Optive, Ophthalmic Solution CI brief — competitive landscape report
- Optive, Ophthalmic Solution updates RSS · CI watch RSS
- Michael D. Straiko, MD portfolio CI